Table 2.
Differential expression and ROC analysis of the 38 candidate DEGs.
| DEGs | Differential analysis | ROC analysis | |||||
|---|---|---|---|---|---|---|---|
| logFC | AveExpr(Tumor) | AveExpr(Normal) | adj.P.Val | Specificity | Sensitivity | AUC | |
| MMP7 | 8.597 | 10.269 | 1.672 | 2.24E−247 | 98.9 | 97.2 | 0.994 |
| KRT80* | 7.498 | 10.622 | 3.124 | 1.62E−317 | 99.7 | 99.0 | 0.998 |
| NOTUM* | 7.363 | 8.637 | 1.274 | 2.09E−175 | 98.6 | 95.5 | 0.993 |
| TNS4 | 6.979 | 12.162 | 5.183 | 9.91E−181 | 98.3 | 91.7 | 0.987 |
| S100P | 6.859 | 12.859 | 6.000 | 2.83E−162 | 91.7 | 96.5 | 0.978 |
| SERPINB5* | 6.676 | 10.504 | 3.829 | 1.35E−162 | 93.4 | 91.0 | 0.970 |
| GRIN2D* | 6.441 | 10.372 | 3.931 | 1.59E−267 | 96.8 | 98.3 | 0.996 |
| UBE2C* | 6.256 | 11.824 | 5.568 | 2.34E−138 | 96.0 | 97.2 | 0.993 |
| RRM2 | 6.203 | 12.360 | 6.157 | 2.62E−128 | 93.1 | 98.6 | 0.987 |
| SAPCD2 | 6.107 | 11.959 | 5.852 | 1.36E−134 | 96.3 | 95.5 | 0.992 |
| VWA2 | 6.032 | 9.438 | 3.406 | 1.29E−227 | 96.8 | 95.5 | 0.993 |
| TPX2 | 6.020 | 12.635 | 6.615 | 1.96E−149 | 95.4 | 98.3 | 0.994 |
| WNT2 | 5.954 | 8.294 | 2.341 | 6.37E−216 | 98.9 | 93.8 | 0.993 |
| TOP2A* | 5.555 | 13.049 | 7.494 | 2.35E−141 | 94.8 | 96.5 | 0.991 |
| STRA6 | 5.416 | 7.839 | 2.423 | 4.36E−175 | 98.3 | 91.3 | 0.981 |
| OTX1 | 5.411 | 6.538 | 1.127 | 1.21E−222 | 98.9 | 93.4 | 0.985 |
| TRIM29 | 5.307 | 11.420 | 6.113 | 1.93E−195 | 98.6 | 92.0 | 0.990 |
| INHBA* | 5.167 | 10.480 | 5.313 | 3.06E−167 | 96.8 | 92.4 | 0.982 |
| SGOL1 | 5.057 | 8.763 | 3.707 | 1.11E−146 | 99.7 | 93.1 | 0.989 |
| TRIB3*# | 4.798 | 11.587 | 6.789 | 1.96E−218 | 97.1 | 98.6 | 0.996 |
| TRIP13 | 4.755 | 10.238 | 5.484 | 1.35E−204 | 97.7 | 99.7 | 0.997 |
| TESC | 4.410 | 10.367 | 5.957 | 2.79E−162 | 95.1 | 90.7 | 0.954 |
| ZWINT | 4.361 | 11.312 | 6.951 | 5.32E−124 | 90.8 | 95.5 | 0.976 |
| SALL4* | 4.249 | 7.514 | 3.265 | 8.32E−158 | 96.8 | 90.7 | 0.972 |
| SPTBN2* | 4.032 | 10.730 | 6.699 | 5.31E−219 | 98.3 | 99.0 | 0.993 |
| RP11-386G11.5* | 3.577 | 5.779 | 2.202 | 7.02E−165 | 96.3 | 93.1 | 0.984 |
| TMEM97 | 3.373 | 11.728 | 8.355 | 1.33E−164 | 96.8 | 95.5 | 0.992 |
| TOMM34* | 3.230 | 12.094 | 8.865 | 1.15E−167 | 99.4 | 93.1 | 0.991 |
| TMEM206* | 2.650 | 9.031 | 6.381 | 1.57E−180 | 98.9 | 96.2 | 0.996 |
| WDR43* | 2.578 | 11.841 | 9.263 | 6.30E−148 | 97.4 | 99.7 | 0.996 |
| TMEFF2 | − 3.729 | 1.225 | 4.954 | 2.34E−167 | 92.8 | 93.4 | 0.966 |
| STMN4# | − 4.236 | 1.416 | 5.651 | 6.62E−161 | 94.5 | 91.3 | 0.962 |
| FAM135B# | − 4.303 | 1.583 | 5.885 | 4.34E−165 | 96.0 | 90.3 | 0.966 |
| GLP2R | − 4.818 | 4.532 | 9.349 | 2.26E−175 | 98.0 | 98.3 | 0.985 |
| RERGL | − 4.894 | 1.734 | 6.628 | 4.72E−163 | 90.5 | 93.1 | 0.968 |
| SFRP5 | − 6.143 | 2.305 | 8.448 | 4.49E−164 | 96.0 | 90.0 | 0.964 |
| SCN7A | − 6.757 | 3.803 | 10.560 | 2.82E−157 | 93.7 | 90.7 | 0.969 |
| PLP1 | − 7.039 | 3.251 | 10.290 | 4.04E−181 | 96.8 | 95.5 | 0.979 |
The differential analysis was performed by limma “package” in R. ROC analysis was carried out using MedCalc software. Genes with “*”showed the tumor stage-positive related genes (P < 0.05). Gene with “#”showed the survival-related genes (P < 0.05).